Email
10 NOVEMBER 2023 VOLUME 25 ISSUE 45
| From | Weekly NewsDigest <[email protected]> |
| Subject | 10 NOVEMBER 2023 VOLUME 25 ISSUE 45 |
| Date | November 10, 2023 10:32 PM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
10 NOVEMBER 2023 VOLUME 25 ISSUE 45
View this email in your browser ([link removed])
[link removed] November 10, 2023
10 NOVEMBER 2023 VOLUME 25 ISSUE 45
Media Coverage
** Government Leaders Reaffirm Their Commitment To Accelerate HIV Prevention Efforts To Reduce New HIV Infection ([link removed])
------------------------------------------------------------
With just two years left to attain the 2025 HIV prevention target of fewer than 370 000 new HIV infections annually, the world is not on track. In 2022, 1.3 million people became infected with HIV – the urgency to accelerate progress cannot be overemphasized.
NOVEMBER 10, 2023 | General | UNAIDS
** LISTEN: The Anti-HIV Jab Is Coming to SA. Find Out When and How ([link removed])
------------------------------------------------------------
In 2022, ViiV Healthcare, the company that makes a revolutionary but expensive HIV prevention injection, announced it was working on a non-profit price for countries such as South Africa. The jab, called CAB-LA (short for long-acting cabotegravir), has to be taken every two months and can lower someone’s chances of contracting HIV through sex to virtually zero.
NOVEMBER 10, 2023 | General | Behikisisa
** Nearly 13% of Participants in an African Cohort Maintain HIV Control Off Treatment ([link removed])
------------------------------------------------------------
Of over four thousand South African and Zambian participants with HIV who provided samples, nearly a quarter were off treatment and 13% of the latter were found to control the virus. Women were twice as likely to be controllers, while other demographic characteristics did not influence viral control.
NOVEMBER 9, 2023 | Treatment | aidsmap
** Rwanda: After Hitting Global Target, Rwanda Sets Eyes On Achieving 100 Percent HIV Treatment ([link removed])
------------------------------------------------------------
Rwanda is one of the countries that have made significant achievements in managing HIV/AIDS, having reached the 95-95-95 target set by the Joint United Nations Programme on HIV/AIDS (UNAIDS). The 95-95-95 target aims at diagnosing 95 per cent of all HIV-positive individuals, providing antiretroviral therapy (ART) for 95 per cent of those diagnosed, and achieving viral suppression for 95 per cent of those treated by 2030.
NOVEMBER 8, 2023 | Treatment | AllAfrica
** Can HIV Be Cured Using Gene Editing? We Will Soon Find Out ([link removed])
------------------------------------------------------------
HIV, the virus that causes Aids, was first identified in 1983. To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check. However, there is still no cure. A small biotech company in San Francisco called Excision BioTherapeutics is trying to change that with its infusion, called EBT-101.
NOVEMBER 8, 2023 | Cure | The Conversation
** Many Mpox Patients Have Other Sexually Transmitted Infections, Study Shows ([link removed])
------------------------------------------------------------
A large proportion of mpox patients in Chicago last year and early this year also had other sexually transmitted infections (STIs) such as HIV, predisposing them to severe mpox and potentially contributing to spread of the virus, finds a study led by Chicago Department of Public Health researchers.
NOVEMBER 8 2023 | STIs | CIDRAP
** Care for Diabetes or High Blood Pressure Can Be Delivered Alongside HIV Care in African Clinics ([link removed])
------------------------------------------------------------
Integrating care of diabetes and high blood pressure for people without HIV into existing HIV clinic systems in primary care in Uganda and Tanzania had no negative effect on the outcomes of people with HIV, an African research group reports in The Lancet.
NOVEMBER 7, 2023 | General | aidsmap
** More People Living Longer With HIV/AIDS in China, Figures Show ([link removed])
------------------------------------------------------------
The prevalence of HIV/AIDS in China has surged in the past 20 years, as improved treatment means people are living longer with the disease, according to official data. Figures published in October by China’s Center for Disease Control and Prevention (CDC) showed that between 2002 and 2021, the prevalence rate of reported HIV/AIDS cases rose from 1.09 per 100,000 people to 79.62, an increase of more than 7,000%.
NOVEMBER 7, 2023 | General | The Guardian
** I ([link removed]) nfants Are Born With Syphilis in Growing Numbers, a Sign of a Wider Epidemic ([link removed])
------------------------------------------------------------
The rise in sexually transmitted infections in the United States has taken a particularly tragic turn: More than 3,700 cases of congenital syphilis were reported in 2022, roughly 11 times the number recorded a decade ago, according to data released on Tuesday by the Centers for Disease Control and Prevention.
NOVEMBER 7, 2023 | STIs | The New York Times
** Syphilis in Babies Reflects Health System Failures ([link removed])
------------------------------------------------------------
The number of babies born with syphilis in the United States is surging. Increased and innovative syphilis testing and treatment can reduce the number of babies born with syphilis and improve health during pregnancy.
NOVEMBER 7, 2023 | STIs | CDC
** HIV Prevention Drugs for Older Americans May Be Free Under New Biden Proposal ([link removed])
------------------------------------------------------------
A proposed federal policy aims to protect older Americans from contracting HIV by offering free preventive medication, the latest effort to catch up to much of Europe and Africa in stemming the spread of the virus. Under the plan from the Biden administration, Medicare would cover patients' full cost of preexposure prophylaxis drugs, which prevent HIV transmission.
NOVEMBER 7, 2023 | PrEP | ABC News
** Leading Innovators in Modified Vector HIV-1 Vaccines for the Pharmaceutical Industry ([link removed])
------------------------------------------------------------
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: modified vector human immunodeficiency virus (HIV)-1 vaccines.
NOVEMBER 7, 2023 | HIV Vaccine | Pharmaceutical Technology
** Not Implementing Generic PrEP Programs for Young MSM Would Be ‘Throwing Away’ Lives, Money ([link removed])
------------------------------------------------------------
Implementing generic PrEP programs for young men who have sex with men at risk for HIV — a group known to have adherence and engagement issues — would reduce new infections and be cost-effective, according to a study. “It is critically important that preventive tools such as pre-exposure prophylaxis (PrEP) be made available to those who can benefit most from them. In the U.S., about 20% of new HIV diagnoses occur among youth aged 13 to 24 years, and young men who have sex with men (YMSM) account for 81% of the new diagnoses within this age group,” Anne M. Neilan, MD, an infectious disease specialist at Massachusetts General Hospital, told Healio.
NOVEMBER 6, 2023 | General | Healio
** Hepatitis B Vaccine May Work Better After Hepatitis C Cure ([link removed])
------------------------------------------------------------
People successfully treated for hepatitis C virus (HCV) infection who have a past history of hepatitis B virus (HBV) vaccine failure are more responsive to another round of vaccination, according to study findings were published in the Journal of Infectious Diseases. With their immune system thrown into disarray, people with hepatitis C may not respond as well to vaccination compared with the general population.
NOVEMBER 6, 2023 | STIs | POZ Magazine
** Tampon That Tests for STIs Created by British Startup ([link removed])
------------------------------------------------------------
A tampon is being repurposed to screen for sexually transmitted infections, with the at-home test aiming to encourage more women to seek treatment. The gynaecological health startup Daye has launched an STI diagnostic tampon, which uses a polymerase chain reaction (PCR) test to check for chlamydia, gonorrhoea, trichomonas, mycoplasma and ureaplasma, with the tampon used in place of a swab or speculum.
NOVEMBER 6, 2023 | STIs | The Guardian
** Stigma Could Affect Mothers Disclosing HIV Status to Children ([link removed])
------------------------------------------------------------
HIV stigma was found to be associated with lower odds of mothers in the United States disclosing their HIV status to their children, according to a study published in Journal of the International AIDS Society.
NOVEMBER 4, 2023 | General | AJMC
** CRISPR Cure for HIV Now Tested in 3 Patients ([link removed])
------------------------------------------------------------
California-based biotech company Excision BioTherapeutics has shared data from the first human clinical trial of a CRISPR cure for HIV — and it’s both encouraging and frustratingly light on details. The challenge: HIV is no longer the death sentence it once was, thanks largely to antiretroviral therapy (ART), daily medications that can decrease the amount of the virus in a person’s blood to levels that are undetectable and untransmittable.
NOVEMBER 4, 2023 | Cure | Big Think
Published Research
** Evaluation of Multiple Data Sources for Predicting Increased Need for HIV Prevention Among Cisgender Women: Understanding Missed Opportunities for Pre-Exposure Prophylaxis (PrEP) ([link removed])
------------------------------------------------------------
Ciswomen constitute a disproportionately low percentage of pre-exposure prophylaxis for HIV prevention (PrEP) users compared to men. Despite PrEP’s effectiveness, women are 5.25 times less likely to take PrEP than men. Identifying women who have increased reasons for HIV prevention and educating and offering PrEP to these women is crucial to reducing HIV transmission and overall health equity.
NOVEMBER 9, 2023 | PrEP | BMC Infectious Diseases
** Efficacy and Safety of Long-Acting Cabotegravir Compared With Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine To Prevent HIV Infection in Cisgender Men and Transgender Women Who Have Sex With Men 1 Year After Study Unblinding: A Secondary ([link removed])
------------------------------------------------------------
Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV prevention efficacy of long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) compared with tenofovir disoproxil fumarate plus emtricitabine daily oral PrEP.
NOVEMBER 9, 2023 | PrEP | The Lancet HIV
** Tracking Global Resources and Capacity for Health Research: Time To Reassess Strategies and Investment Decisions ([link removed])
------------------------------------------------------------
The COVID-19 pandemic and more recently the Monkeypox outbreak emphasize the urgency and importance of improving the availability and equitable distribution of resources for health research across rich and poor countries. Discussions about the persistent imbalances in resource allocation for health research between rich and poor countries are not new, but little or no progress has been made in redressing these imbalances over the years.
SEPTEMBER 11, 2023 | General | Health Research Policy and Systems
** Promoting HIV Care Continuum Outcomes Among People Who Use Drugs and Alcohol: A Systematic Review of Randomized Trials Evaluating Behavioral HIV Care Interventions Published From 2011 to 2023 ([link removed])
------------------------------------------------------------
Substance use remains a robust predictor of HIV infection and a serious impediment to HIV care continuum progression for people living with HIV. The primary research question of this systematic review is focused on understanding the extent to which behavioral HIV care interventions have been efficacious in helping people who live with HIV and who use substances along the HIV care continuum.
NOVEMBER 7, 2023 | General | BMC Public Health
** Sero-Prevalence of Syphilis Infection Among People Living With HIV in Sierra Leone: A Cross-Sectional Nationwide Hospital-Based Study ([link removed])
------------------------------------------------------------
Globally, there were an estimated 7.1 million new syphilis infections in 2020, with more than 30% of these new infections reported in African countries such as Sierra Leone. Despite this, there is no HIV-specific syphilis screening program in Sierra Leone.
NOVEMBER 6, 2023 | STIs | BMC Infectious Diseases
** A Comparative Study of Transgender Women Accessing HIV Testing via Face-to-Face and Telemedicine Services in Chiang Mai, Thailand During the COVID-19 Pandemic and Their Risk of Being HIV-Positive ([link removed])
------------------------------------------------------------
Due to the restricted availability of health services in Thailand, there are still some transgender women (TGW) who do not have access to HIV counseling and testing. Telehealth, which is accessible to individuals who are reluctant to undergo face-to-face interviewing, played an especially important role during the COVID-19 epidemic.
NOVEMBER 4, 2023 | Testing | BMC Public Health
** Prevention Strategies for Sexually Transmitted Infections, HIV, and Viral Hepatitis in Europe ([link removed](23)00157-6/fulltext)
------------------------------------------------------------
The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region, especially in the Central and Eastern subregions, are hindered by healthcare disparities, data gaps, and limited resources. In this comprehensive narrative review, we aim to highlight both achievements and persisting challenges while also exploring new developments that could significantly impact the prevention of these infections in the near future.
OCTOBER 26, 2023 | General | The Lancet Regional Health Europe
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed]) [link removed]
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423 [email protected] (mailto:[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])
View this email in your browser ([link removed])
[link removed] November 10, 2023
10 NOVEMBER 2023 VOLUME 25 ISSUE 45
Media Coverage
** Government Leaders Reaffirm Their Commitment To Accelerate HIV Prevention Efforts To Reduce New HIV Infection ([link removed])
------------------------------------------------------------
With just two years left to attain the 2025 HIV prevention target of fewer than 370 000 new HIV infections annually, the world is not on track. In 2022, 1.3 million people became infected with HIV – the urgency to accelerate progress cannot be overemphasized.
NOVEMBER 10, 2023 | General | UNAIDS
** LISTEN: The Anti-HIV Jab Is Coming to SA. Find Out When and How ([link removed])
------------------------------------------------------------
In 2022, ViiV Healthcare, the company that makes a revolutionary but expensive HIV prevention injection, announced it was working on a non-profit price for countries such as South Africa. The jab, called CAB-LA (short for long-acting cabotegravir), has to be taken every two months and can lower someone’s chances of contracting HIV through sex to virtually zero.
NOVEMBER 10, 2023 | General | Behikisisa
** Nearly 13% of Participants in an African Cohort Maintain HIV Control Off Treatment ([link removed])
------------------------------------------------------------
Of over four thousand South African and Zambian participants with HIV who provided samples, nearly a quarter were off treatment and 13% of the latter were found to control the virus. Women were twice as likely to be controllers, while other demographic characteristics did not influence viral control.
NOVEMBER 9, 2023 | Treatment | aidsmap
** Rwanda: After Hitting Global Target, Rwanda Sets Eyes On Achieving 100 Percent HIV Treatment ([link removed])
------------------------------------------------------------
Rwanda is one of the countries that have made significant achievements in managing HIV/AIDS, having reached the 95-95-95 target set by the Joint United Nations Programme on HIV/AIDS (UNAIDS). The 95-95-95 target aims at diagnosing 95 per cent of all HIV-positive individuals, providing antiretroviral therapy (ART) for 95 per cent of those diagnosed, and achieving viral suppression for 95 per cent of those treated by 2030.
NOVEMBER 8, 2023 | Treatment | AllAfrica
** Can HIV Be Cured Using Gene Editing? We Will Soon Find Out ([link removed])
------------------------------------------------------------
HIV, the virus that causes Aids, was first identified in 1983. To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check. However, there is still no cure. A small biotech company in San Francisco called Excision BioTherapeutics is trying to change that with its infusion, called EBT-101.
NOVEMBER 8, 2023 | Cure | The Conversation
** Many Mpox Patients Have Other Sexually Transmitted Infections, Study Shows ([link removed])
------------------------------------------------------------
A large proportion of mpox patients in Chicago last year and early this year also had other sexually transmitted infections (STIs) such as HIV, predisposing them to severe mpox and potentially contributing to spread of the virus, finds a study led by Chicago Department of Public Health researchers.
NOVEMBER 8 2023 | STIs | CIDRAP
** Care for Diabetes or High Blood Pressure Can Be Delivered Alongside HIV Care in African Clinics ([link removed])
------------------------------------------------------------
Integrating care of diabetes and high blood pressure for people without HIV into existing HIV clinic systems in primary care in Uganda and Tanzania had no negative effect on the outcomes of people with HIV, an African research group reports in The Lancet.
NOVEMBER 7, 2023 | General | aidsmap
** More People Living Longer With HIV/AIDS in China, Figures Show ([link removed])
------------------------------------------------------------
The prevalence of HIV/AIDS in China has surged in the past 20 years, as improved treatment means people are living longer with the disease, according to official data. Figures published in October by China’s Center for Disease Control and Prevention (CDC) showed that between 2002 and 2021, the prevalence rate of reported HIV/AIDS cases rose from 1.09 per 100,000 people to 79.62, an increase of more than 7,000%.
NOVEMBER 7, 2023 | General | The Guardian
** I ([link removed]) nfants Are Born With Syphilis in Growing Numbers, a Sign of a Wider Epidemic ([link removed])
------------------------------------------------------------
The rise in sexually transmitted infections in the United States has taken a particularly tragic turn: More than 3,700 cases of congenital syphilis were reported in 2022, roughly 11 times the number recorded a decade ago, according to data released on Tuesday by the Centers for Disease Control and Prevention.
NOVEMBER 7, 2023 | STIs | The New York Times
** Syphilis in Babies Reflects Health System Failures ([link removed])
------------------------------------------------------------
The number of babies born with syphilis in the United States is surging. Increased and innovative syphilis testing and treatment can reduce the number of babies born with syphilis and improve health during pregnancy.
NOVEMBER 7, 2023 | STIs | CDC
** HIV Prevention Drugs for Older Americans May Be Free Under New Biden Proposal ([link removed])
------------------------------------------------------------
A proposed federal policy aims to protect older Americans from contracting HIV by offering free preventive medication, the latest effort to catch up to much of Europe and Africa in stemming the spread of the virus. Under the plan from the Biden administration, Medicare would cover patients' full cost of preexposure prophylaxis drugs, which prevent HIV transmission.
NOVEMBER 7, 2023 | PrEP | ABC News
** Leading Innovators in Modified Vector HIV-1 Vaccines for the Pharmaceutical Industry ([link removed])
------------------------------------------------------------
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: modified vector human immunodeficiency virus (HIV)-1 vaccines.
NOVEMBER 7, 2023 | HIV Vaccine | Pharmaceutical Technology
** Not Implementing Generic PrEP Programs for Young MSM Would Be ‘Throwing Away’ Lives, Money ([link removed])
------------------------------------------------------------
Implementing generic PrEP programs for young men who have sex with men at risk for HIV — a group known to have adherence and engagement issues — would reduce new infections and be cost-effective, according to a study. “It is critically important that preventive tools such as pre-exposure prophylaxis (PrEP) be made available to those who can benefit most from them. In the U.S., about 20% of new HIV diagnoses occur among youth aged 13 to 24 years, and young men who have sex with men (YMSM) account for 81% of the new diagnoses within this age group,” Anne M. Neilan, MD, an infectious disease specialist at Massachusetts General Hospital, told Healio.
NOVEMBER 6, 2023 | General | Healio
** Hepatitis B Vaccine May Work Better After Hepatitis C Cure ([link removed])
------------------------------------------------------------
People successfully treated for hepatitis C virus (HCV) infection who have a past history of hepatitis B virus (HBV) vaccine failure are more responsive to another round of vaccination, according to study findings were published in the Journal of Infectious Diseases. With their immune system thrown into disarray, people with hepatitis C may not respond as well to vaccination compared with the general population.
NOVEMBER 6, 2023 | STIs | POZ Magazine
** Tampon That Tests for STIs Created by British Startup ([link removed])
------------------------------------------------------------
A tampon is being repurposed to screen for sexually transmitted infections, with the at-home test aiming to encourage more women to seek treatment. The gynaecological health startup Daye has launched an STI diagnostic tampon, which uses a polymerase chain reaction (PCR) test to check for chlamydia, gonorrhoea, trichomonas, mycoplasma and ureaplasma, with the tampon used in place of a swab or speculum.
NOVEMBER 6, 2023 | STIs | The Guardian
** Stigma Could Affect Mothers Disclosing HIV Status to Children ([link removed])
------------------------------------------------------------
HIV stigma was found to be associated with lower odds of mothers in the United States disclosing their HIV status to their children, according to a study published in Journal of the International AIDS Society.
NOVEMBER 4, 2023 | General | AJMC
** CRISPR Cure for HIV Now Tested in 3 Patients ([link removed])
------------------------------------------------------------
California-based biotech company Excision BioTherapeutics has shared data from the first human clinical trial of a CRISPR cure for HIV — and it’s both encouraging and frustratingly light on details. The challenge: HIV is no longer the death sentence it once was, thanks largely to antiretroviral therapy (ART), daily medications that can decrease the amount of the virus in a person’s blood to levels that are undetectable and untransmittable.
NOVEMBER 4, 2023 | Cure | Big Think
Published Research
** Evaluation of Multiple Data Sources for Predicting Increased Need for HIV Prevention Among Cisgender Women: Understanding Missed Opportunities for Pre-Exposure Prophylaxis (PrEP) ([link removed])
------------------------------------------------------------
Ciswomen constitute a disproportionately low percentage of pre-exposure prophylaxis for HIV prevention (PrEP) users compared to men. Despite PrEP’s effectiveness, women are 5.25 times less likely to take PrEP than men. Identifying women who have increased reasons for HIV prevention and educating and offering PrEP to these women is crucial to reducing HIV transmission and overall health equity.
NOVEMBER 9, 2023 | PrEP | BMC Infectious Diseases
** Efficacy and Safety of Long-Acting Cabotegravir Compared With Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine To Prevent HIV Infection in Cisgender Men and Transgender Women Who Have Sex With Men 1 Year After Study Unblinding: A Secondary ([link removed])
------------------------------------------------------------
Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV prevention efficacy of long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) compared with tenofovir disoproxil fumarate plus emtricitabine daily oral PrEP.
NOVEMBER 9, 2023 | PrEP | The Lancet HIV
** Tracking Global Resources and Capacity for Health Research: Time To Reassess Strategies and Investment Decisions ([link removed])
------------------------------------------------------------
The COVID-19 pandemic and more recently the Monkeypox outbreak emphasize the urgency and importance of improving the availability and equitable distribution of resources for health research across rich and poor countries. Discussions about the persistent imbalances in resource allocation for health research between rich and poor countries are not new, but little or no progress has been made in redressing these imbalances over the years.
SEPTEMBER 11, 2023 | General | Health Research Policy and Systems
** Promoting HIV Care Continuum Outcomes Among People Who Use Drugs and Alcohol: A Systematic Review of Randomized Trials Evaluating Behavioral HIV Care Interventions Published From 2011 to 2023 ([link removed])
------------------------------------------------------------
Substance use remains a robust predictor of HIV infection and a serious impediment to HIV care continuum progression for people living with HIV. The primary research question of this systematic review is focused on understanding the extent to which behavioral HIV care interventions have been efficacious in helping people who live with HIV and who use substances along the HIV care continuum.
NOVEMBER 7, 2023 | General | BMC Public Health
** Sero-Prevalence of Syphilis Infection Among People Living With HIV in Sierra Leone: A Cross-Sectional Nationwide Hospital-Based Study ([link removed])
------------------------------------------------------------
Globally, there were an estimated 7.1 million new syphilis infections in 2020, with more than 30% of these new infections reported in African countries such as Sierra Leone. Despite this, there is no HIV-specific syphilis screening program in Sierra Leone.
NOVEMBER 6, 2023 | STIs | BMC Infectious Diseases
** A Comparative Study of Transgender Women Accessing HIV Testing via Face-to-Face and Telemedicine Services in Chiang Mai, Thailand During the COVID-19 Pandemic and Their Risk of Being HIV-Positive ([link removed])
------------------------------------------------------------
Due to the restricted availability of health services in Thailand, there are still some transgender women (TGW) who do not have access to HIV counseling and testing. Telehealth, which is accessible to individuals who are reluctant to undergo face-to-face interviewing, played an especially important role during the COVID-19 epidemic.
NOVEMBER 4, 2023 | Testing | BMC Public Health
** Prevention Strategies for Sexually Transmitted Infections, HIV, and Viral Hepatitis in Europe ([link removed](23)00157-6/fulltext)
------------------------------------------------------------
The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region, especially in the Central and Eastern subregions, are hindered by healthcare disparities, data gaps, and limited resources. In this comprehensive narrative review, we aim to highlight both achievements and persisting challenges while also exploring new developments that could significantly impact the prevention of these infections in the near future.
OCTOBER 26, 2023 | General | The Lancet Regional Health Europe
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed]) [link removed]
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423 [email protected] (mailto:[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])
Message Analysis
- Sender: n/a
- Political Party: n/a
- Country: n/a
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp